ATC CODE
- L04AB02
INDICATIONS AND NEMLC RECOMMENDATIONS
INDICATIONS AND NEMLC RECOMMENDATIONS 1
INDICATION
- Fistulising Crohn’s Disease.
NEMLC RECOMMENDATION
- Not Approved .
REVIEW INDICATORS
- A considerable change in the price of the drug.
DATE RATIFIED
- 20 September 2007
INDICATIONS AND NEMLC RECOMMENDATIONS 2
INDICATION
- Rheumatoid Arthritis.
NEMLC RECOMMENDATION
- Not Approved .
REVIEW INDICATORS
- Demonstration in randomized trials of reduction in clinically significant endpoints, e.g. hospitalizations, joint replacements, etc.
- Evidence of sustained, clinically relevant improvement upon withdrawal of infliximab.
- A significant reduction in the price of the medicine.
DATE RATIFIED
- 13 March 2008